Also found in: Wikipedia.


(do-ri-pen-em) ,


(trade name)


Therapeutic: anti infectives
Pharmacologic: carbapenems
Pregnancy Category: B


Infections caused by susceptible organisms including:
  • complicated intra-abdominal infections,
  • complicated urinary tract infections, including pyelonephritis.


Inhibits bacterial cell wall formation.

Therapeutic effects

Bactericidal action against susceptible bacteria.
Active against the following gram-negative organisms: Acinetobacter baumanii, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Pseudomonas aeruginosa.Also active against the following gram-positive organisms: Streptococcus constellatus and S. intermedius.Anaerobic spectrum includes Bacteroides caccae, B. fragilis, B. thetaiotaomicron, B.uniformis, B. vulgatus, and Peptostreptococcus micros.


Absorption: IV administration results in complete bioavailability.
Distribution: Penetrates renal and peritoneal and retroperitoneal tissues and fluids.
Metabolism and Excretion: 71% excreted unchanged in urine; minimal metabolism.
Half-life: 1 hr.

Time/action profile (blood levels)

IVunknownend of infusion8 hr*
*Normal renal function


Contraindicated in: Hypersensitivity to doripenem, other carbapenems, or beta-lactams.
Use Cautiously in: Renal impairment (↑ risk of seizures; dose reduction recommended if CCr <50 mL/min); Geriatric: Consider age-related ↓ in renal function when choosing dose; Lactation: Use cautiously during lactation; Pediatric: Safety not established.

Adverse Reactions/Side Effects

Central nervous system

  • seizures (life-threatening)
  • headache (most frequent)


  • pseudomembranous colitis (life-threatening)
  • nausea (most frequent)
  • diarrhea
  • ↑ liver enzymes


  • anemia (most frequent)
  • thrombocytopenia


  • stevens-johnson syndrome (life-threatening)
  • toxic epidermal necrolysis (life-threatening)
  • pruritis
  • rash


  • phlebitis


  • allergic reactions including anaphylaxis (life-threatening)
  • infection with resistant organisms
  • superinfection


Drug-Drug interaction

May ↓ serum valproate levels (↑ risk of seizures).May ↓ blood levels of valproic acid ; this may result in loss of seizure control.Probenecid ↓ renal clearance and ↑ blood levels.


Intravenous (Adults) 500 mg every 8 hr.

Renal Impairment

Intravenous (Adults) CCr 30–50 mL/min—250 mg every 8 hr; CCr >10–<30 mL/min—250 mg every 12 hr.


Powder for injection (requires reconstitution): 500 mg/vial

Nursing implications

Nursing assessment

  • Assess patient for infection (vital signs; appearance of wound, sputum, urine, and stool; WBC) at beginning of and during therapy.
  • Obtain a history before initiating therapy to determine previous use of and reactions to penicillins, cephalosporins, or carbapenems. Persons with a negative history of penicillin sensitivity may still have an allergic response.
  • Obtain specimens for culture and sensitivity before initiating therapy. First dose may be given before receiving results.
  • Observe patient for signs and symptoms of anaphylaxis (rash, pruritus, laryngeal edema, wheezing). Discontinue the drug and notify the physician immediately if these occur. Have epinephrine, an antihistamine, and resuscitative equipment close by in the event of an anaphylactic reaction.
  • Monitor bowel function. Diarrhea, abdominal cramping, fever, and bloody stools should be reported to health care professional promptly as a sign of pseudomembranous colitis. May begin up to several weeks following cessation of therapy.
  • Assess patient for skin rash frequently during therapy. Discontinue at first sign of rash; may be life-threatening. Stevens-Johnson syndrome may develop. Treat symptomatically; may recur once treatment is stopped.
  • Lab Test Considerations: May cause ↑ AST, ALT, serum alkaline phosphatase levels.
    • May cause anemia.

Potential Nursing Diagnoses

Risk for infection (Indications,  Side Effects)


  • Do not confuse Doribax with Zovirax.
  • May switch to appropriate oral therapy after at least 3 days of parenteral therapy, once clinical improvement has been demonstrated.
  • Intravenous Administration
  • Intermittent Infusion: Reconstitute 500-mg vial with 10 mL of sterile injection or 0.9% NaCl and shake gently to form a suspension of 50 mg/mL. Diluent: Withdraw the resulting solution using a 21-gauge needle and add it to 100 mL of 0.9% NaCl or D5W; gently shake until clear. For moderate or severe renal impairment, withdraw 55 mL of this solution from the bag and discard. Solution should be clear and colorless to slightly yellow.Concentration: Final concentration is 4.5 mg/mL. Suspension is stable for 1 hr prior to dilution in infusion bag. Administer within 8 hr of reconstitution with 0.9% NaCl or 4 hr of reconstitution with D5W at room temperature or 24 hr if refrigerated; do not freeze.
  • Rate: Administer over 1 hr. Do not administer direct IV.
  • Y-Site Compatibility: acyclovir, amikacin, aminophylline, amiodarone, anidulafungin, atropine, azithromycin, bumetanide, calcium gluconate, carboplatin, caspofungin, ceftaroline, ciprofloxacin, cisplatin, cyclophosphamide, cyclosporine, daptomycin, dexamethasone, digoxin, diltiazem, diphenhydramine, dobutamine, docetaxel, dopamine, doxorubicin, enalaprilat, esmolol, esomeprazole, etoposide phosphate, famotidine, fentanyl, fluconazole, fluorouracil, foscarnet, fucosemide, gemcitabine, gentamicin, granisetron, heparin, hydrocortisone sodium succinate, hydromorphone, ifosfamide, insulin, labetalol, levofloxacin, linezolid, lorazepam, magnesium sulfate, mannitol, meperidine, methotrexate, methylprednisolone, metoclopramide, metronidazole, micafungin, midazolam, milrinone, morphine, moxifloxacin, norepinephrine, ondansetron, paclitaxel, pantoprazole, phenobarbital, phenylephrine, potassium chloride, ranitidine, sodium bicarbonate, sodium phosphates, tacrolimus, telavancin, tigecycline, tobramycin, vancomycin, voriconazole, zidovudine
  • Y-Site Incompatibility: Do not mix with or physically add to solutions containing other medications,diazepam, potassium phosphates, propofol

Patient/Family Teaching

  • Advise patient to report the signs of superinfection (black, furry overgrowth on the tongue; vaginal itching or discharge; loose or foul-smelling stools) and allergy. Consult health care professional before treating with antidiarrheals.
  • Caution patient to notify health care professional if rash or fever and diarrhea occur, especially if stool contains blood, pus, or mucus. Advise patient not to treat diarrhea without consulting health care professional. May occur up to several weeks after discontinuation of medication.

Evaluation/Desired Outcomes

  • Resolution of the signs and symptoms of infection. Length of time for complete resolution depends on the organism and site of infection. Duration may be extended up to 14 days for patients with concurrent bacteremia.


a miscellaneous antiinfective.
indications This drug is used to treat serious infections caused by Acinetobacter baumannii, Bacteroides caccae, B. fragilis, B. thetaiotaomicron, B. uniformis, B. vulgates, Escherichia coli, Klebsiella pneumoniae, Peptostreptococcus micros, Proteus mirabilis, Pseudomonas aeruginosa, Streptococcus contellatus, S. intermedius; complicated urinary tract infections; pyelonephritis; and complicated intraabdominal infections.
contraindications Viral infection and known hypersensitivity to this drug or to meropenem, imipenem, penicillin, or beta-lactam prohibit the use of this drug.
adverse effects Adverse effects of this drug include headache, diarrhea, nausea, vomiting, urticaria, phlebitis, erythema at the injection site, and pruritis. Life-threatening side effects include seizures, pseudomembranous colitis, hepatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, and anaphylaxis. A common side effect is rash.
References in periodicals archive ?
The new definition (resistant to imipenem, meropenem, doripenem, or ertapenem or documentation that the isolate possesses a carbapenemase) is to be used with current CLSI breakpoints (10).
Therapeutic use: Doripenem (7) is a carbapenem bactericidal antimicrobial that inactivates essential penicillin-binding proteins in the cell wall, inhibiting cell wall biosynthesis, thereby resulting in bacterial cell death.
BEERSE, Belgium, July 19 /PRNewswire/ -- Janssen-Cilag International NV announced today that the European Medicines Agency (EMEA) has accepted for review a Marketing Authorization Application (MAA) for doripenem, an investigational carbapenem antibiotic for the treatment of nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP), complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).
5 g/d for 28 d After identification of pathogen Continuation of doripenem At discharge Oral amoxicillin, 1,500 mg/d, and minocycline, 200 mg/d, until follow-up visit Postoperative complications None Outcome Survived * CT, computed tomography; +, positive; -, negative; L, left; R, right; MLST, multilocus sequence typing; ST, sequence type; CC, clonal complex; A, adenine; G, guanine; T, threonine; I, isoleucine; D, aspartic acid; G, glycine.
Contract awarded for event 3153/2013 doripenem, parenteral use powder 500 mg 20 ml vial
The antibiotic pipeline today * Novel Compound Class MOA Dalbavancin Lipoglycopeptide No ([dagger]) Iclaprim Diaminopyrimidine No Oritavancin Glycopeptide No Telavancin Lipoglycopeptide Yes ([double dagger]) Ceftobiprole Cephalosporin ([section]) No Cethromycin Ketolide No Doripenem Carbapenem No Faropenem Penem No Prulifloxacin Quinolone No Compound Formulation Status Dalbavancin IV Filed Iclaprim IV Phase 3 Oritavancin IV Phase 3 Telavancin IV Phase 3 Ceftobiprole IV Filed Cethromycin Oral Phase 3 Doripenem IV Approved Faropenem Oral Filed ([paragraph]) Prulifloxacin Oral Phase 3 * Adapted from ref.
The Company has provided such innovative medicines as Crestor and Doripenem, which have been successfully delivered to millions of patients.
org), were as follows: sulbactam/ampicillin, >128 mg/L; piperacillin, >128 mg/L; tazobactam/piperacillin, >128 mg/L; cefotaxime, >64 mg/L; ceftazidime, >64 mg/L; aztreonam, 64 mg/L; cefmetazole, >128 mg/L; imipenem, 8 mg/L; meropenem, 32 mg/L; and doripenem, 32 mg/L.
Contract awarded for event 3081/2013 doripenem powder for use parenteral 500 mg vial 20 ml
Data from this study show that although ertapenem (Merck's Invanz), meropenem (AstraZeneca's Merrem, generics), and imipenem-cilastatin (Merck's Primaxin) have near equal high rates of hospital formulary inclusion and formulary uptake of doripenem (J&J's Doribax) has rapidly climbed over the last five years, the perceived therapeutic equivalence of carbapenems is leading P&T committees to limit the number of carbapenems on formulary.
Other excluded studies were those that did not distinguish the outcomes for infected patients from those for colonized patients and studies that reported on isolates resistant to a carbapenem other than imipenem, meropenem, or doripenem.
MICs of amikacin, aztreonam, cefotaxime, cefepime, ciprofloxacin, colistin, doripenem, ertapenem, gentamicin, imipenem, meropenem, polymyxin B, tetracycline, tigecycline, and trimethoprim/sulfamethoxazole were determined by using reference broth microdilution (BMD) with panels prepared in-house according to Clinical and Laboratory Standards Institute (Wayne, PA, USA) guidelines (16) and stored at -70 [degrees]C until use.